LightPath Technologies reported a strong fourth quarter with revenue rising 73% year-over-year to $21.16 million, surpassing analyst expectations. Full-year revenue grew 93% to $71.70 million, reflecting solid market demand and a strategic shift to higher-value products. Despite this, the company posted an EPS of -$0.02, missing estimates but improving from last year's loss. Operational profitability improved with a gross margin of 39.4% and the fourth consecutive quarter of positive adjusted EBITDA at $2.10 million, supported by a robust $110.90 million backlog, signaling continued growth potential.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Zions Bancorporation is set to report its Q3 2026 earnings on October 19, with analysts expecting earnings per share around $1.64 to $1.65 and revenue near $890 million to $894 million, reflecting growth from the previous year. The company has also a...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
